Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze

Neuroscience Letters

Volumn 361, Issue 1-3, 2004, Pages 128-131

  Alcalay, Roy N ^a   Giladi, Eliezer ^a   Pick, Chaim G ^a   Gozes, Illana ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Aging; Anxiety; Intranasal; Neuroprotection; Rodent; Vasoactive intestinal peptide

Indexed keywords

AMINO ACID; ASPARAGINYLALANYLPROLYLVALYLSERYLISOLEUCYLPROLYLGLUTAMINE; NEUROPEPTIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EXPOSURE; MALE; MAZE TEST; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, INTRANASAL; AGE FACTORS; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; DRUG ADMINISTRATION SCHEDULE; MALE; MAZE LEARNING; MEMORY; MICE; NEUROPROTECTIVE AGENTS; OLIGOPEPTIDES; TREATMENT OUTCOME;

EID: 2342561068     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2003.12.005     Document Type: Article

References (20)

1. Andrieux A., Salin P.A., Vernet M., Kujala P., Baratier J., Gory-Faure S., Bosc C., Pointu H., Proietto D., Schweitzer A., Denarier E., Klumperman J., Job D. The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders. Genes Dev. 16:2002;2350-2364
2. Bassan M., Zamostiano R., Davidson A., Pinhasov A., Giladi E., Perl O., Bassan H., Blat C., Gibney G., Glazner G., Brenneman D.E., Gozes I. Complete sequence of a novel protein containing a femtomolar activity dependent neuroprotective peptide. J. Neurochem. 72:1999;1283-1293
3. Belzung C., Griebel G. Measuring normal and pathological anxiety like behaviour in mice: a review. Behav. Brain Res. 125:2001;141-149
4. Beni Adani L., Gozes I., Cohen Y., Assaf Y., Steingart R.A., Brenneman D.E., Eisenberg O., Trembolver V., Shohami E. A peptide derived from activity dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice. J. Pharmacol. Exp. Ther. 296:2001;57-63
5. Crawley J.N. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities and specific behavioral tests. Brain Res. 835:1999;18-26
6. American Psychiatric Assosiation. DSM-IV, Diagnostic and Statistical Manual of Mental Disorders. 4th Edition:1994;American Psychiatric Assosiation, Washington, DC
7. File S.E. Factors controlling measures of anxiety and responses to novelty in the mouse. Behav. Brain Res. 125:2001;151-157
8. Gordon I., Grauer E., Genis I., Sehayek E., Michaelson D.M. Memory deficits and cholinergic impairments in apolipoprotein E-deficient mice. Neurosci. Lett. 13:1995;1-4
9. Gozes I., Giladi E., Pinhasov A., Bardea A., Brenneman D.E. Activity dependent neurotrophic factor: Intranasal administration of femtomolar acting peptides improve performance in a water maze. J. Pharmacol. Exp. Ther. 293:2000;1091-1098
10. Gozes I., Alcalay R., Giladi E., Pinhasov A., Furman S., Brenneman D.E. NAP accelerates the performance of normal rats in the water maze. J. Mol. Neurosci. 19:2002;175-178
11. Hogg S. A review of the validity and variability of the elevated plus-maze as an animal model of anxiety. Pharmacol. Biochem. Behav. 54:1996;21-30
12. Kanematsu T., Jang I.S., Yamaguchi T., Nagahama H., Yoshimura K., Hidaka K., Matsuda M., Takeuchi H., Misumi Y., Nakayama K., Yamamoto T., Akaike N., Hirata M., Nakayama K. Role of the PLC-related, catalytically inactive protein p130 in GABA(A) receptor function. EMBO J. 21:2002;1004-1011
13. Leker R., Teichner A., Grigoriadis N., Ovadia H., Brenneman D.E., Fridkin M., Giladi E., Romano J., Gozes I. NAP, a femtomolar acting peptide, protects the brain against ischemic injury by reducing apoptotic death. Stroke. 33:2002;1085-1092
14. Lister R.G. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berlin). 92:1987;180-185
15. Morris R. Developments of a water maze procedure for studying spatial learning in the rat. J. Neurosci. Methods. 11:1984;47-60
16. Offen D., Sherki Y., Melamed E., Fridkin M., Brenneman D.E., Gozes I. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res. 854:2000;257-262
17. Romano J., Beni-Adani L., Levy-Nissenbaum O., Brenneman D.E., Shohami E., Gozes I. A single administration of the peptide NAP induces long term protective changes against the consequences of head injury. J. Mol. Neurosci. 18:2002;37-45
18. Spong C.Y., Abebe D.T., Gozes I., Brenneman D.E., Hill J.M. Prevention of fetal demise and growth restriction in a mouse model of fetal alcohol syndrome. J. Pharmacol. Exp. Ther. 297:2001;774-779
19. Zaltzman R., Beni S.M., Giladi E., Pinhasov A., Steingart R.A., Romano J., Shohami E., Gozes I. Injections of the neuroprotective peptide NAP to newborn mice attenuate head-injury-related dysfunction in adults. NeuroReport. 14:2003;481-484
20. Zamostiano R., Pinhasov A., Gelber E., Steingart R.A., Serroussi E., Giladi E., Bassan M., Wollman Y., Eyre H.J., Mulley J.C., Brenneman D.E., Gozes I. Cloning and characterization of the human activity dependent neuroprotective protein. J. Biol. Chem. 276:2001;708-714